The IPO Buzz: Upstream Bio Files Plans for $100 Million IPO
Upstream Bio (UPB Proposed), a Phase 2 clinical biotech focused on severe respiratory disease, filed plans to raise up to $100 million in an IPO, according to its S-1 filing on Wednesday, Sept. 18, 2024. Upstream Bio said it intends to list its stock on the NASDAQ. Upstream Bio’s S-1 filing was disclosed late Wednesday […]
September 19, 2024 Read More